logo
Search
  • 2015 The year that was: Continued success for POA Pharma.

     

    2015 The year that was: Continued success for POA Pharma and international breakthrough for our Metabolic range of products.   

    Export

    Prior to 2015 we had the ambition that our metabolic products, (Antisecretory factor and our IEM range of products) would be commercially available in about 25 countries. At the year end, we were able to enjoy that the figure has risen to 40 countries around the world.

    We initially kept the prognosis conservative, as there always is uncertainties in making accurate forecasts for export transactions, in particular for markets outside Europe. However the unique qualities of the products have proved to be a major reason why so many markets have opened their doors for us.

     

    POA Pharma North America

    In December 2014 POA Pharma Scandinavia AB acquired 20 percent of the shares in NOVAM Nutrition LLC, Oregon / USA. In 2015 POA Pharma increased its stake to 70 percent and is now the majority owner. Thus, POA Pharma North America, as the company is now called, is a part of the POA group and we have commercial access to around 40 % of the global markets for our Medical nutrition products.

     

    Other joys

    In a fair recap of 2015 must also be mentioned:

    In addition to the success of the AF at the World Congress in Rome on Meniere's disease (see below), POA Pharma also successfully participated in SSIEM, Society for the Study of Inborn Errors of Metabolism, a world congress that took place in Lyon, France.

    Our “in house” developed PKU products received deserved attention and further International contacts were made resulting in opening of new international markets.

    During 2015 we also launched a new concept for treatment of IEM patients based on new technology. The first product, presented at SSIEM in Lyon, was PKU shake&GO. The plan is to introduce at least one new product each year.

    Agreements were also signed with companies on two “new” continents – Orpharma in Australia and Cape Medicine in South Africa, for our metabolic products and Antisecretory factor. POA’s in-house developed products for Inborn Error of Metabolism are now available on all continents.

    For our Nordic strategic area we signed an agreement with Desma Healthcare regarding Akineton, a drug for the control of extrapyramidal symptoms occurring due to other medication. To quote Wikipedia:

    “Akineton is on the WHO Model List of Essential Medicines, the most important medications needed in a basic healthcare system”.

     

    Antisecretory factor, AF

    One of the events in 2015 that delighted me most was the mini symposium on Antisecretory factor that was held during the 7th International Symposium on Meniere's Disease and Inner Ear Disordes in Rome, Italy on 17-20 October.

    The Mini symposium´s headline posed the question Antisecretory Factor: A Clinical Innovation in Meniere's Disease? The clinical studies presented at the meeting answered the question with a clear Yes!

     

    AF were given space at the world congress and was documented by scientists from different countries as a relevant and effective treatment of Ménière's disease.

    The symposium has had an immediate and positive effect and Interest in the concept has sky rocketed.

    300 specialists of the 550 specialists from 52 countries gathered in

    Rome took part in the symposium.

    After the congress other scholars and centres from different parts of the world have contacted us.   

    That the world of Meniérè specialists and ENT physicians one day should discover and take advantage of the benefits of Antisecretory factor is a dream I have cherished for many years.

    After the World Congress in Rome this dream seems to be coming true.

     

    Roland Sandström

    Chairman of the Board

    POA Pharma Scandinavia AB

    Leave a reply →